WR Hambrecht comments on Nektar Therapeutics (Nasdaq: NKTR). The firm said street estimates for Exubera sales are too low ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE